HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome

Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS- Mutant NSCLC Is Mediated via Reactivation of the ERK–p90RSK–mTOR Signaling Network

(2017) Suman Chatterjee et al.   MOLECULAR CANCER THERAPEUTICS

Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer

(2017) Giannicola Genovese et al.   NATURE

Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells

(2016) Xin Liu et al.   ANTI-CANCER DRUGS

A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors

(2016) Toshio Shimizu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease

(2016) T Chernova et al.   CELL DEATH AND DIFFERENTIATION

Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse

(2016) Marco Demaria et al.   Cancer Discovery

Suppression of the senescence-associated secretory phenotype (SASP) in human fibroblasts using small molecule inhibitors of p38 MAP kinase and MK2

(2015) Dauren Alimbetov et al.   BIOGERONTOLOGY

Intratumoral Heterogeneity: From Diversity Comes Resistance

(2015) A. Pribluda et al.   CLINICAL CANCER RESEARCH

A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study

(2015) Manish K. Thakur et al.   INVESTIGATIONAL NEW DRUGS

A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors

(2015) Suzanne F. Jones et al.   INVESTIGATIONAL NEW DRUGS

Therapy-induced tumour secretomes promote resistance and tumour progression

(2015) Anna C. Obenauf et al.   NATURE

MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation

(2015) Remi-Martin Laberge et al.   NATURE CELL BIOLOGY

Resistance to HSP90 inhibition involving loss of MCL1 addiction

(2015) S Busacca et al.   ONCOGENE

The DNA damage response induces inflammation and senescence by inhibiting autophagy of GATA4

(2015) C. Kang et al.   SCIENCE

A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations

(2015) Claudia Canino et al.   Oncotarget

The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells

(2015) Roberto Gomez-Casal et al.   Cancers

Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype.

(2015) Mickaël Ohanna et al.   Oncotarget

Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDHhighCD44+ phenotype and sphere-forming capacity

(2014) Lourdes Cortes-Dericks et al.   BMC CANCER

Chromatin maintenance and dynamics in senescence: a spotlight on SAHF formation and the epigenome of senescent cells

(2014) Armelle Corpet et al.   CHROMOSOMA

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

(2014) D. Sarker et al.   CLINICAL CANCER RESEARCH

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer

(2014) Suqin He et al.   INVESTIGATIONAL NEW DRUGS

TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90  and  , Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models

(2014) S. Ohkubo et al.   MOLECULAR CANCER THERAPEUTICS

Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation

(2014) M Cioce et al.   Cell Death & Disease

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer

(2013) M. A. Socinski et al.   CLINICAL CANCER RESEARCH

Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma

(2013) Seo Young Park et al.   EUROPEAN JOURNAL OF CANCER

The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non-Small Cell Lung Cancer Growth

(2013) E. B. Garon et al.   MOLECULAR CANCER THERAPEUTICS

A complex secretory program orchestrated by the inflammasome controls paracrine senescence

(2013) Juan Carlos Acosta et al.   NATURE CELL BIOLOGY

HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer

(2013) C-H Lai et al.   ONCOGENE

Quantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition

(2012) Mikko Taipale et al.   CELL

Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non-Small Cell Lung Cancer

(2012) T. Shimamura et al.   CLINICAL CANCER RESEARCH

Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives

(2012) Nicholas A. Saunders et al.   EMBO Molecular Medicine

Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells

(2012) J Cahu et al.   Cell Death & Disease

Aldehyde dehydrogenase: Its role as a cancer stem cell marker comes down to the specific isoform

(2011) Paola Marcato et al.   CELL CYCLE

Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells

(2011) Yue Wang et al.   CYTOKINE

p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype

(2011) Adam Freund et al.   EMBO JOURNAL

Senescent cells develop a PARP-1 and nuclear factor- B-associated secretome (PNAS)

(2011) M. Ohanna et al.   GENES & DEVELOPMENT

Malignant mesothelioma: Facts, Myths, and Hypotheses

(2011) Michele Carbone et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

(2011) W. Ying et al.   MOLECULAR CANCER THERAPEUTICS

SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells

(2011) C Canino et al.   ONCOGENE

Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model

(2010) Jedd M. Hillegass et al.   Annals of the New York Academy of Sciences

Senescent cells as a source of inflammatory factors for tumor progression

(2010) Albert R. Davalos et al.   CANCER AND METASTASIS REVIEWS

Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models

(2010) Yan Ning et al.   INTERNATIONAL JOURNAL OF CANCER

CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts

(2010) Christophe Ginestier et al.   JOURNAL OF CLINICAL INVESTIGATION

Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: Result in a cohort of 203 resection specimens

(2010) Aneil A. Mujoomdar et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

Secretome-Based Proteomic Profiling of Ras-Transformed MDCK Cells Reveals Extracellular Modulators of Epithelial-Mesenchymal Transition

(2009) Rommel A. Mathias et al.   JOURNAL OF PROTEOME RESEARCH

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90

(2009) K. Lundgren et al.   MOLECULAR CANCER THERAPEUTICS

Protocols to detect senescence-associated beta-galactosidase (SA-βgal) activity, a biomarker of senescent cells in culture and in vivo

(2009) Florence Debacq-Chainiaux et al.   Nature Protocols

let-7 microRNAs in development, stem cells and cancer

(2008) Ingo Büssing et al.   TRENDS IN MOLECULAR MEDICINE

Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor

(2008) Jean-Philippe Coppé et al.   PLOS BIOLOGY